Multicenter Case Registry Study of Lecanemab in Early Alzheimer's Disease in Northwest China
This real-world study suggests that Lecanemab is well-tolerated in clinical use in Northwest China, with manageable adverse effects and no severe adverse events such as ARIA reported to date. The neuropsychological scales keep stable during the 6-month follow-up, but plasma biomarkers showed significant improvement after treatment. A long time follow-up and large sample are needed.
Authors
- Simeng Cui (ORCID: https://orcid.org/0009-0000-9380-4734)
- Shan Wei (ORCID: https://orcid.org/0009-0001-7901-5947)
- Jin Wang
- Ling Gao
- Qiumin Qu
- Peijie Liu
Institutions
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108419
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00